TrueTicker

NIFTY 50 › Healthcare

Healthcare

Sun Pharmaceutical Industries Ltd.

SUNPHARMA on NSE · 19 Nov 2026

NIFTY 50 F&O

1,900.00 ▲ +1.52 % on the day

Overview Quality Outlook Risk & rank Results Accounts Options Guidance & governance

Guidance tracker

What SUNPHARMA guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
04 Nov 2026Sun Pharmaceutical filed the transcript of its Q2 FY27 earnings conference call held on 4 November 2026 under Regulation 30 of the SEBI LODR Regulations. Q2 FY27 consolidated sales were INR1,61,000 million, up 11.8% year on year; EBITDA was INR47,439 million (up 4.8%) with a 29.3% margin; reported net profit after... NSE copy No results filed since
06 Aug 2026Sun Pharma filed the transcript of its Q1 FY27 earnings conference call held on 6 August 2026 under Regulation 30 of the SEBI LODR Regulations. Consolidated sales for Q1 FY27 were INR 151,836 million, up 10.1% year-on-year; EBITDA was INR 44,177 million (up 2.7%) with a margin of 28.9%; reported net profit after... NSE copy -36.2 %+11.9 %+0.9 %
29 May 2026Sun Pharma filed the transcript of its Q4 FY26 earnings conference call held on 29 May 2026 under Regulation 30. Management (CFO Jayashree Satagopan) reported Q4 FY26 sales of INR 145,598 million (up 13.6% YoY), EBITDA of INR 39,542 million (EBITDA margin 27.1%), and reported net profit of INR 27,140 million;... NSE copy +27.0 %+10.5 %-0.5 %
05 May 2026Sun Pharma filed the transcript of its investor call of 05 May 2026 on the acquisition of Organon & Company under Regulation 30. Dilip Shanghvi said Organon is roughly the same size and profitability as Sun was when it acquired Ranbaxy, that the deal is for about 20-22% of Sun's value, and that Sun will take on... NSE copy +26.2 %+12.8 %-2.5 %
27 Apr 2026Sun Pharmaceutical Industries filed an investor presentation dated 27 April 2026 under Regulation 30 of the SEBI LODR Regulations, to be uploaded on its website. The presentation cites FY25 revenue of $6.2B+, cash of $3.1B+, and 20% of revenue from its Innovative Medicines business, and describes Sun as the #1... NSE copy +26.2 %+12.8 %-2.5 %
11 Nov 2025Sun Pharmaceutical filed the transcript of its Q2 FY26 earnings conference call held on 11 November 2025. Management (CFO Jayashree Satagopan) reported Q2 FY26 consolidated sales of INR144,052 million, up 8.6% year on year, EBITDA of INR45,271 million (up 14.9%, margin 31.3%) and net profit after tax of INR31,180... NSE copy +16.0 %+13.5 %+0.9 %
06 Aug 2025Sun Pharma filed the transcript of its Q1 FY26 earnings conference call held on 6 August 2025, under Regulation 30 of the SEBI LODR Regulations. Management reported Q1 FY26 consolidated sales of Rs. 1,37,861 million (up 10.1% YoY), EBITDA of Rs. 43,017 million (up 19.2%) and reported net profit of Rs. 22,786... NSE copy +2.6 %+8.9 %-0.2 %
29 May 2025Sun Pharma filed the transcript of its Q4 FY25 earnings conference call held on May 29, 2025, under Regulation 30. FY25 sales were Rs. 520,412 million (up 9%); FY25 reported net profit was Rs. 109,290 million; Q4 FY25 sales were Rs. 128,156 million (up 8.5%) and Q4 reported net profit was Rs. 21,499 million after... NSE copy -19.6 %+9.5 %-1.6 %
06 Feb 2025Sun Pharma filed the transcript of its Q3 FY25 earnings conference call held on February 6, 2025. Management reported Q3 FY25 consolidated sales of INR 134,369 million, up 10.5% year-on-year (8.9% excluding milestone income in ROW), and EBITDA of INR 40,090 million with a 29.3% margin. Adjusted net profit excluding... NSE copy -19.0 %+8.1 %-2.0 %
04 Nov 2024Sun Pharmaceutical filed the transcript of its Q2 FY25 earnings conference call held on November 4, 2024, under Regulation 30 of SEBI LODR. Management (CFO C. S. Muralidharan) said Q2 FY25 sales were Rs. 132,642 million, up 10.5% year-on-year, and net profit after tax was Rs. 30,402 million, up 28%; EBITDA margin... NSE copy +15.0 %+10.5 %-0.1 %
29 May 2024Sun Pharma filed the transcript of its Q4 FY24 earnings conference call held on May 29, 2024, under Regulation 30. Management (CFO C. S. Muralidharan) said FY24 sales were INR477,585 million, up 10.4%, and Q4 FY24 sales were INR118,133 million, up 10.1% year-on-year; reported Q4 net profit was INR26,546 million.... NSE copy +40.2 %+6.0 %-0.2 %
08 Nov 2023Sun Pharma filed the transcript of its Q2 FY24 earnings conference call held on November 8, 2023. CFO C.S. Muralidharan said Q2 FY24 sales were INR120,031 million, up 11% year-on-year, and net profit was INR23,755 million, up 5%; reported EPS was INR9.90 per share. Management said consolidated net cash was USD1.9... NSE copy +16.5 %+10.1 %+3.4 %

Filings tagged as guidance, newest first (12 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
04 Nov 2026Legal or regulatorySun Pharmaceutical filed the transcript of its Q2 FY27 earnings conference call held on 4 November 2026 under Regulation 30 of the SEBI LODR Regulations. Q2 FY27 consolidated sales were INR1,61,000 million, up 11.8% year on year; EBITDA was INR47,439 million (up 4.8%) with a 29.3% margin; reported net profit after... NSE copy
13 Oct 2026Credit ratingSun Pharmaceutical Industries filed an intimation under Regulation 30 of SEBI LODR on credit ratings dated 13 October 2026. CRISIL assigned 'Crisil AAA/Stable' to proposed NCDs of Rs 15,000 crore and reaffirmed 'Crisil AAA/Stable' long-term and 'Crisil A1+' short-term ratings (CP programme Rs 4,000 crore). ICRA... NSE copy
12 Oct 2026Management changeSun Pharmaceutical Industries filed the outcome of its board meeting held on 12 October 2026, which ran from 5:00 PM to 5:50 PM IST. The board approved issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis, in one or more tranches, for an aggregate amount not... NSE copy
08 Sep 2026Credit ratingSun Pharmaceutical Industries Limited filed an intimation under Regulation 30 of SEBI LODR on international credit ratings assigned on 08 September 2026. Moody's Ratings assigned a Long-Term Issuer Credit Rating of Baa1 with Stable Outlook; S&P Global Ratings assigned a Long-Term Issuer Credit Rating of BBB+ with... NSE copy
05 Aug 2026Credit ratingSun Pharmaceutical Industries filed an update under Regulation 30 of the SEBI LODR on its credit rating, dated 05 August 2026. CRISIL Ratings has removed the 'Rating Watch with Developing Implications' status on the company's long-term bank facilities. CRISIL has reaffirmed the rating on those facilities at 'CRISIL... NSE copy
31 Jul 2026Legal or regulatoryBoard of Sun Pharmaceutical Industries approved unaudited standalone and consolidated financial results for Q1 FY2026-27 (quarter ended June 30, 2026), with limited review report, on 31 July 2026. Standalone total revenue from operations for the quarter was ₹57,411.3 million versus ₹56,985.9 million... [see note]... NSE copy
29 May 2026Legal or regulatorySun Pharma filed the transcript of its Q4 FY26 earnings conference call held on 29 May 2026 under Regulation 30. Management (CFO Jayashree Satagopan) reported Q4 FY26 sales of INR 145,598 million (up 13.6% YoY), EBITDA of INR 39,542 million (EBITDA margin 27.1%), and reported net profit of INR 27,140 million;... NSE copy
07 May 2026Credit ratingSun Pharmaceutical Industries intimated under Regulation 30 of SEBI LODR that CRISIL Ratings reaffirmed its long-term bank facilities at 'Crisil AAA' and short-term bank facilities and commercial paper at 'Crisil A1+'. CRISIL placed the 'Crisil AAA' long-term rating on Rating Watch with Developing Implications,... NSE copy
22 Nov 2025Legal or regulatorySun Pharmaceutical Industries Limited filed an intimation under Regulation 30 of SEBI LODR regarding the effective date of a Composite Scheme of Arrangement. The certified copy of the NCLT order sanctioning the Scheme was filed with the Registrar of Companies on 22 November 2025. The Scheme becomes effective from... NSE copy
05 Nov 2025Legal or regulatorySun Pharmaceutical Industries' board met on 05 November 2025 and approved unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2025, with the auditor's limited review report. Standalone revenue from operations for the quarter ended 30.09.2025 was ₹56,985.9 million (Q2 FY25... NSE copy
08 Oct 2025Legal or regulatorySun Pharmaceutical Industries Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, informing that the NCLT, Ahmedabad Bench, approved a Composite Scheme of Arrangement by its order dated 7 October 2025. The scheme involves amalgamation of five wholly-owned subsidiaries (Sun... NSE copy
06 Aug 2025Legal or regulatorySun Pharma filed the transcript of its Q1 FY26 earnings conference call held on 6 August 2025, under Regulation 30 of the SEBI LODR Regulations. Management reported Q1 FY26 consolidated sales of Rs. 1,37,861 million (up 10.1% YoY), EBITDA of Rs. 43,017 million (up 19.2%) and reported net profit of Rs. 22,786... NSE copy
31 Jul 2025Management changeSun Pharmaceutical Industries reported unaudited standalone Q1 FY2025-26 results (quarter ended 30 June 2025) in its board meeting outcome filing dated 31 July 2025, with a limited review report from SRBC & CO LLP. Standalone total revenue from operations for the quarter was ₹5,601.96 crore (₹56,019.6 million), and... NSE copy
29 May 2025Legal or regulatorySun Pharma filed the transcript of its Q4 FY25 earnings conference call held on May 29, 2025, under Regulation 30. FY25 sales were Rs. 520,412 million (up 9%); FY25 reported net profit was Rs. 109,290 million; Q4 FY25 sales were Rs. 128,156 million (up 8.5%) and Q4 reported net profit was Rs. 21,499 million after... NSE copy
22 May 2025Management changeBoard of Sun Pharmaceutical Industries met on 22 May 2025 and approved audited standalone and consolidated results for the quarter and year ended 31 March 2025, with unmodified audit opinions. Board recommended a final dividend of Rs. 5.50 per equity share of Re. 1 each for FY 2024-25, subject to AGM approval;... NSE copy
06 Feb 2025Legal or regulatorySun Pharma filed the transcript of its Q3 FY25 earnings conference call held on February 6, 2025. Management reported Q3 FY25 consolidated sales of INR 134,369 million, up 10.5% year-on-year (8.9% excluding milestone income in ROW), and EBITDA of INR 40,090 million with a 29.3% margin. Adjusted net profit excluding... NSE copy
04 Nov 2024Legal or regulatorySun Pharmaceutical filed the transcript of its Q2 FY25 earnings conference call held on November 4, 2024, under Regulation 30 of SEBI LODR. Management (CFO C. S. Muralidharan) said Q2 FY25 sales were Rs. 132,642 million, up 10.5% year-on-year, and net profit after tax was Rs. 30,402 million, up 28%; EBITDA margin... NSE copy
07 Aug 2024Legal or regulatorySun Pharmaceutical filed the transcript of its Q1 FY25 earnings conference call held on August 7, 2024. Management (CFO C. S. Muralidharan) reported Q1 FY25 consolidated sales of Rs. 125,245 million, up 6.3% year-on-year, EBITDA of Rs. 36,076 million (28.5% margin) and net profit after tax of Rs. 28,356 million, up... NSE copy
01 Aug 2024Management changeSun Pharmaceutical's board approved unaudited standalone and consolidated results for Q1 FY2024-25 (quarter ended June 30, 2024) on August 1, 2024, with a limited review report from SR BC & Co LLP. Standalone total revenue from operations for the quarter was Rs 44,980.7 million, against Rs 44,660.7 million in the... NSE copy
22 Jun 2024Legal or regulatorySun Pharma filed a press release on results of a Phase 1 multiple ascending-dose study of GL0034 (Utreglutide) in obese adults, presented orally at the American Diabetes Association 84th Scientific Sessions on June 21, 2024. Study had 24 healthy obese male participants (BMI ≥ 28 kg/m2); cohort 2 showed absolute... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (33 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in